Indeed, using a targeted proteomic approach, we have also published that T2D AAA patients have a distinct plasma inflammatory profile, compared to ND AAA subjects, with a reduced expression of circulating CCL19 and CCL23 chemokines, as well as an increased expression of TNSF14, a member of the TNFα superfamily [10]. The gene discussed is CCL19; the disease is triple-A syndrome.